Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Safety, Immunogenicity, and Preliminary Efficacy of an Administration Schedule of FMP1 and SmithKlineBeecham Biologicals' Candidate Malaria Vaccine RTS,S Each Adjuvanted With SBAS2, Given Concomitantly in Separate Injections

NCT01556945 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT01556945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01556945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Safety, Immunogenicity, and Preliminary Efficacy of an Administration Schedule of FMP1 and SmithKlineBeecham Biologicals' Candidate Malaria Vaccine RTS,S Each Adjuvanted With SBAS2, Given Concomitantly in Separate Injections
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2001
Completion date
Not reported
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, falciparum